The Ohio State University

The development of chimeric antigen receptor T-cell therapy has revolutionized treatment for patients with advanced blood cancers.

My career started in the 1980s, coinciding with the start of the HIV epidemic. I worked with internal medicine residents; our attending physician was board certified in internal medicine and oncology. Between managing complex opportunistic infections seen in patients with HIV and patients with cancer, my interest in ID went from 10 to 1,000! I transitioned to The Ohio State University Medical Center as the first ID PharmD.

Patellar apprehension in knee flexion of greater than 60° could identify patients with patella alta, severe trochlear dysplasia and increased tibial tubercle-trochlear groove distance, according to recently presented study results.

The FDA expanded the approval of nivolumab plus ipilimumab for treatment of lung cancer, according to the agents’ manufacturer.

Inflammatory bowel disease is a debilitating condition that takes a lifetime of treatment to control. Over the years, medical therapies for the disease have evolved greatly, but the approval of anti-tumor necrosis factor alpha therapy for the treatment of Crohn’s disease in 1998 was a turning point in IBD treatment management.